We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LEQEMBI (Eisai Australia Pty Ltd)
Product name
LEQEMBI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
471 (255 working days)
Active ingredients
lecanemab
Registration type
NCE/ NBE
Indication
LEQEMBI is indicated in adult patients with a diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) that are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes.
Beta amyloid evidence consistent with Alzheimer’s disease (AD) should be confirmed using a validated test prior to initiating treatment